Teacher Retirement System of Texas Purchases 4,328 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Teacher Retirement System of Texas lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 18.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,159 shares of the biopharmaceutical company's stock after purchasing an additional 4,328 shares during the quarter. Teacher Retirement System of Texas' holdings in Intra-Cellular Therapies were worth $2,352,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ITCI. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth $32,000. GAMMA Investing LLC lifted its holdings in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Intra-Cellular Therapies in the fourth quarter worth about $96,000. Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies during the third quarter worth approximately $97,000. Finally, Quarry LP increased its stake in Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after acquiring an additional 1,300 shares during the last quarter. Institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Trading Up 0.0 %

Shares of Intra-Cellular Therapies stock traded up $0.06 on Friday, hitting $131.81. 1,584,630 shares of the company traded hands, compared to its average volume of 1,391,525. The company has a market cap of $14.04 billion, a PE ratio of -151.50 and a beta of 0.69. The stock's 50 day moving average price is $129.12 and its 200-day moving average price is $99.80. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.87.

Remove Ads

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ITCI shares. Mizuho cut Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Leerink Partnrs cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Piper Sandler restated a "neutral" rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their price target for the company from $119.00 to $132.00 in a report on Friday, January 31st. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.